Prevalent tuberculosis and mortality among HAART initiators

doi:10.1097/QAD.0b013e328351f6b8

. 2012 Mar 27;26(6):770-3.

doi: 10.1097/QAD.0b013e328351f6b8.

Prevalent tuberculosis and mortality among HAART initiators

Daniel Westreich¹, Matthew P Fox, Annelies Van Rie, Mhairi Maskew

Affiliations

PMID: 22313956
PMCID: PMC3348652
DOI: 10.1097/QAD.0b013e328351f6b8

Prevalent tuberculosis and mortality among HAART initiators

Daniel Westreich et al. AIDS. 2012.

. 2012 Mar 27;26(6):770-3.

doi: 10.1097/QAD.0b013e328351f6b8.

Authors

Daniel Westreich¹, Matthew P Fox, Annelies Van Rie, Mhairi Maskew

Affiliation

¹ Department of Obstetrics and Gynecology, Duke Global Health Institute, Duke University, Durham, North Carolina, USA. daniel.westreich@duke.edu

PMID: 22313956
PMCID: PMC3348652
DOI: 10.1097/QAD.0b013e328351f6b8

Abstract

The effect of tuberculosis on mortality in people initiating highly-active antiretroviral therapy (HAART) remains unclear; here, we strengthened a previous cohort analysis. Multivariate Cox proportional hazards models were used to assess the association of baseline tuberculosis and time to all-cause mortality among HAART initiators. In reanalysis, treatment for tuberculosis at time of HAART initiation remained unassociated with increased risks of all-cause mortality, with adjusted hazard ratios ranging from 1.00 to 1.09.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE

The authors have no financial, consultant, institutional or other conflict of interest to declare.

Comment in

Assessing the impact of prevalent tuberculosis on mortality among antiretroviral treatment initiators: accurate tuberculosis diagnosis is essential.
Lawn SD, Gupta A, Wood R. Lawn SD, et al. AIDS. 2012 Aug 24;26(13):1730-1; author reply 1728-9. doi: 10.1097/QAD.0b013e3283565ebe. AIDS. 2012. PMID: 22874482 Free PMC article. No abstract available.

Cited by

Incident pregnancy and time to death or AIDS among HIV-positive women receiving antiretroviral therapy.
Westreich D, Maskew M, Evans D, Firnhaber C, Majuba P, Sanne I. Westreich D, et al. PLoS One. 2013;8(3):e58117. doi: 10.1371/journal.pone.0058117. Epub 2013 Mar 8. PLoS One. 2013. PMID: 23520489 Free PMC article. Clinical Trial.
Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease.
Périssé AR, Smeaton L, Chen Y, La Rosa A, Walawander A, Nair A, Grinsztejn B, Santos B, Kanyama C, Hakim J, Nyirenda M, Kumarasamy N, Lalloo UG, Flanigan T, Campbell TB, Hughes MD; P E A R L S study team of the ACTG. Périssé AR, et al. PLoS One. 2013 Dec 31;8(12):e83643. doi: 10.1371/journal.pone.0083643. eCollection 2013. PLoS One. 2013. PMID: 24391801 Free PMC article. Clinical Trial.
Assessing the impact of prevalent tuberculosis on mortality among antiretroviral treatment initiators: accurate tuberculosis diagnosis is essential.
Lawn SD, Gupta A, Wood R. Lawn SD, et al. AIDS. 2012 Aug 24;26(13):1730-1; author reply 1728-9. doi: 10.1097/QAD.0b013e3283565ebe. AIDS. 2012. PMID: 22874482 Free PMC article. No abstract available.
High incidence of tuberculosis in the first year of antiretroviral therapy in the Botswana National antiretroviral therapy programme between 2011 and 2015.
Mupfumi L, Moyo S, Shin SS, Wang Q, Zetola N, Molebatsi K, Nnawa J, Kgwaadira BT, Bewlay L, Chebani T, Iketleng T, Mogashoa T, Makhema J, Musonda RM, Essex M, Kasvosve I, Gaseitsiwe S. Mupfumi L, et al. AIDS. 2019 Dec 1;33(15):2415-2422. doi: 10.1097/QAD.0000000000002363. AIDS. 2019. PMID: 31764106 Free PMC article.
Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.
Corbett EL, MacPherson P. Corbett EL, et al. Int J Tuberc Lung Dis. 2013 Sep;17(9):1125-38. doi: 10.5588/ijtld.13.0117. Int J Tuberc Lung Dis. 2013. PMID: 23928165 Free PMC article. Review.

See all "Cited by" articles

References

1. Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS ONE. 2010;5:e15241. - PMC - PubMed
1. Westreich D, MacPhail P, Van Rie A, Malope-Kgokong B, Ive P, Rubel D, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009;23:707–715. - PMC - PubMed
1. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Jama. 2006;296:782–793. - PubMed
1. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. Aids. 2006;20:2355–2360. - PubMed
1. Dronda F, Sobrino P, Hernandez-Novoa B, Caro-Murillo AM, Montero M, Iribarren JA, et al. Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections. Curr HIV Res. 2011;9:229–236. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS ONE. 2010;5:e15241. - PMC - PubMed

[2] Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS ONE. 2010;5:e15241. - PMC - PubMed

[3] Westreich D, MacPhail P, Van Rie A, Malope-Kgokong B, Ive P, Rubel D, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009;23:707–715. - PMC - PubMed

[4] Westreich D, MacPhail P, Van Rie A, Malope-Kgokong B, Ive P, Rubel D, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009;23:707–715. - PMC - PubMed

[5] Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Jama. 2006;296:782–793. - PubMed

[6] Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Jama. 2006;296:782–793. - PubMed

[7] Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. Aids. 2006;20:2355–2360. - PubMed

[8] Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. Aids. 2006;20:2355–2360. - PubMed

[9] Dronda F, Sobrino P, Hernandez-Novoa B, Caro-Murillo AM, Montero M, Iribarren JA, et al. Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections. Curr HIV Res. 2011;9:229–236. - PubMed

[10] Dronda F, Sobrino P, Hernandez-Novoa B, Caro-Murillo AM, Montero M, Iribarren JA, et al. Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections. Curr HIV Res. 2011;9:229–236. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prevalent tuberculosis and mortality among HAART initiators

Affiliation

Prevalent tuberculosis and mortality among HAART initiators

Authors

Affiliation

Abstract

Conflict of interest statement

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical